top of page

Oct 1

Mathai Mammen provides an update on the latest at FogPharma, and his philosophy of following the cadence of science, not the calendar

The Chairman and CEO of FogPharma describes the progress the company has made this year, including on the lead β-catenin/TCF4 inhibitor program, and a partnership on an alpha-particle radioligand platform. Plus, leadership advice and how technology has changed science.

Brought to you by:

Recent Posts

The Co-Founder and CTO of Seoul based Organoid Sciences walks us through how the company is using organoids for regenerative medicine, CRO services, and precision medicine

The CEO of Seoul based Bridge Biotherapeutics discusses the importance of drug development experience - a lead program in IPF is scheduled to have a key phase 2 readout next spring

Seoul and Gaithersburg based D&D Pharmatech is leveraging its expertise in peptide engineering for metabolic, fibrotic, and CNS conditions - including a handful of oral GLP-1 based medicines

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh

bottom of page